Summary of Key Points from the Conference Call of Jianyou Co., Ltd. Company Overview - **Company**: Jianyou Co., Ltd. - **Industry**: Pharmaceutical, specifically focusing on heparin raw materials and high-end formulations Core Insights and Arguments - **Transformation to High-End Formulations**: Jianyou has successfully transitioned from a heparin raw material supplier to a high-end formulation company, with over 70% of revenue now coming from this segment, covering both domestic and international markets, particularly in the U.S. [3][4][9] - **Sales Growth Amidst Price Pressure**: Despite facing price pressures due to centralized procurement in China, the company has managed to maintain sales volume growth, although sales revenue has slightly declined. The pressure from centralized procurement is easing [4][12]. - **Impact of Heparin Raw Material Market**: The heparin raw material market has been underperforming, leading to a significant inventory write-down of 12.4 billion yuan in 2023, resulting in a negative net profit. However, a mild recovery is expected in 2024, with a projected net profit turnaround of approximately 8.0 to 10.5 billion yuan [6][22]. - **Revenue and Profit Forecast**: Jianyou's revenue is expected to grow from 42.39 billion yuan in 2024 to 71.90 billion yuan in 2026, with net profits projected to rise from 9.46 billion yuan to 16.18 billion yuan during the same period [7][22]. - **R&D and Sales Efficiency**: The company has seen a continuous increase in R&D expenditure, reaching 5.9 billion yuan in 2023, which is about 15% of revenue, while sales expenses have decreased from 15% in 2022 to around 10% in 2023 [8][9]. - **High Gross Margin Focus**: Jianyou is focusing on high-margin formulation business, with the gross margin contribution from this segment increasing significantly, even amidst challenges in the heparin raw material sector [10][12]. Additional Important Insights - **Regional Revenue Breakdown**: In 2023, domestic revenue was 10.48 billion yuan, while international revenue was 28.75 billion yuan, with the U.S. subsidiary contributing 16.3 billion yuan, a 37.7% increase year-on-year. The overseas revenue share is expected to rise to 78.6% in the first half of 2024 [11][12]. - **Product Portfolio and Market Expansion**: The company has over 50 products in the U.S. market and is actively expanding into other regions, including South America and North Africa, leveraging partnerships with domestic firms for product development [3][5][14]. - **Production Capacity and Compliance**: Jianyou has 12 production lines approved by the FDA, enhancing its competitive edge in high-end markets [17]. - **Risks and Challenges**: Key risks include intensified market competition, centralized procurement risks, fluctuations in raw material prices, and exchange rate volatility due to the significant share of overseas business [23]. This summary encapsulates the critical aspects of Jianyou Co., Ltd.'s recent conference call, highlighting its strategic direction, financial outlook, and the challenges it faces in the pharmaceutical industry.

Investment Rating - The report initiates coverage with a "Buy" rating for the company [5]. Core Views - The company is transitioning from heparin raw materials to high-end injectable formulations, with a significant increase in the proportion of its formulation business, which accounted for over 70% of revenue in 2023 [1][17]. - The company has established a strong presence in the U.S. market, with over 50 products running and a sales revenue of 1.63 billion yuan in 2023, marking it as one of the largest Chinese pharmaceutical companies in the U.S. high-end formulation market [2][19]. - The heparin raw material business is stabilizing after a period of decline, with a projected mild recovery in 2024, which is expected to positively impact net profit [3][19]. Company Overview - The company is one of the largest global suppliers of heparin raw materials and formulations, with over 80 formulation varieties operating in more than 60 countries [1][10]. - The company has a mature R&D, quality, registration, and sales team in the U.S., leading the domestic industry in ANDA approvals [1][10]. Formulation Business - The formulation business is the main source of revenue and profit for the company, with sales increasing from 762 million yuan in 2019 to 2.77 billion yuan in 2023, representing 70.50% of total revenue [22]. - The company has been actively expanding its domestic market presence through successful bids in national procurement, although sales have faced pressure due to price reductions [24][40]. - The company is also expanding its global footprint, with overseas revenue exceeding 70% of total revenue in 2023, driven by a robust product pipeline and strategic market entry [19][41]. Heparin Raw Material Business - The heparin raw material business has shown a stable production trend, with a slight recovery expected in 2024, which will help mitigate previous losses from inventory write-downs [3][19]. - The company recorded a write-down of 1.24 billion yuan in 2023 due to declining heparin prices, impacting net profit [3][19]. Financial Forecast and Investment Recommendations - The company is expected to achieve revenues of 4.24 billion yuan, 5.57 billion yuan, and 7.19 billion yuan for 2024, 2025, and 2026, respectively, with corresponding net profits of 946 million yuan, 1.16 billion yuan, and 1.62 billion yuan [4][19]. - The report anticipates continued growth in the formulation business, which will drive overall performance improvements [4][19].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [5]. Core Views - The company is transitioning towards high-end formulations, with a significant increase in the proportion of its formulation business, which accounted for over 70% of total revenue in 2023. This shift reflects a successful transformation from a traditional raw material supplier to an international sterile injection enterprise [1][17]. - The company has established a strong presence in the U.S. market, with over 50 products operational and a leading position in ANDA approvals among domestic peers. The U.S. subsidiary generated sales of 1.63 billion yuan in 2023, marking it as one of the largest Chinese pharmaceutical companies engaged in high-end formulation sales in the U.S. [2][19]. - The report forecasts revenue growth for the company, projecting revenues of 4.24 billion yuan, 5.57 billion yuan, and 7.19 billion yuan for 2024, 2025, and 2026, respectively, with corresponding net profits of 946 million yuan, 1.16 billion yuan, and 1.62 billion yuan [4][19]. Summary by Sections Company Overview - The company is one of the largest global suppliers of heparin raw materials and formulations, with over 80 formulation varieties marketed in more than 60 countries. It has been increasing R&D investments to support its transition to high-end formulations [1][10]. Formulation Business - The formulation business is the main source of revenue and profit for the company, with sales increasing from 762 million yuan in 2019 to 2.77 billion yuan in 2023, representing 70.50% of total revenue. The gross profit from this segment also rose significantly during the same period [22][23]. - The company has been actively expanding its domestic market presence through successful bids in national procurement, although sales have faced pressure due to price reductions [24][40]. Heparin Raw Materials - The heparin raw material business has shown a mild recovery, with stable production levels. However, the company faced a significant inventory impairment in 2023, leading to a net profit decrease of 1.05 billion yuan. A recovery in the global heparin market is expected in 2024, with potential reversals of inventory impairments [3][19]. Financial Forecast and Investment Recommendations - The report anticipates substantial growth in the company's overseas formulation business, which is expected to drive overall performance. The projected earnings per share (EPS) for 2024, 2025, and 2026 are 0.59 yuan, 0.72 yuan, and 1.00 yuan, respectively [4][19].

Investment Rating - The report gives a "Buy" rating for the company [5]. Core Views - The company is transitioning towards high-end formulations, with a significant increase in the proportion of formulation business, which accounted for over 70% of total revenue in 2023. This shift reflects a successful transformation from a traditional raw material supplier to an international sterile injection enterprise [1][17]. - The company has established a strong presence in the U.S. market, with over 50 products operational and a leading position in ANDA approvals among domestic peers. The U.S. subsidiary generated sales of 1.63 billion yuan in 2023, marking it as one of the largest Chinese pharmaceutical companies engaged in high-end formulation sales in the U.S. [2][19]. - The report forecasts revenue growth driven by overseas formulation business, with projected revenues of 4.24 billion yuan, 5.57 billion yuan, and 7.19 billion yuan for 2024, 2025, and 2026, respectively [4][19]. Summary by Sections Company Overview - The company is one of the largest global suppliers of heparin raw materials and formulations, with over 80 formulation varieties in more than 60 countries. It has been increasing R&D investments to support its transition to high-end formulations [1][10]. Formulation Business - The formulation business is the main source of revenue and profit for the company, with sales increasing from 762 million yuan in 2019 to 2.77 billion yuan in 2023, representing 70.50% of total revenue. The gross profit from this segment also rose significantly during the same period [22][23]. - The company has been actively participating in national procurement, which has helped maintain growth in domestic formulation sales despite some price pressures [24][40]. Heparin Raw Materials - The heparin raw material business has seen a mild recovery, with stable production levels. However, the company faced a significant inventory impairment charge of 1.24 billion yuan in 2023 due to declining prices, which impacted net profit [3][19]. - The report anticipates a recovery in the global heparin market in 2024, with a potential reversal of inventory impairment provisions, which could positively affect net profit [3][19]. Financial Forecast and Investment Recommendations - The company is expected to achieve a turnaround in profitability, with projected net profits of 946 million yuan, 1.16 billion yuan, and 1.62 billion yuan for 2024, 2025, and 2026, respectively. The earnings per share (EPS) are forecasted to be 0.59 yuan, 0.72 yuan, and 1.00 yuan for the same years [4][19]. - The report emphasizes the company's commitment to high-margin formulation business and its ongoing expansion into international markets, which are expected to drive future growth [17][19].

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for its stock performance [5][7]. Core Views - The company is positioned as a leading player in the heparin raw material market, with a strong potential for growth in its API business due to improving market conditions [3][4]. - The company is focusing on its sterile injection formulations, which are experiencing rapid growth in overseas markets, supported by a robust product matrix and strategic acquisitions [4][61]. - The global biosimilar market is expected to expand significantly, and the company is well-positioned to capitalize on this trend through both self-developed products and strategic partnerships [5][67]. Summary by Sections 1. Company Overview - The company has transitioned from a traditional heparin raw material supplier to a high-end injection formulation and biosimilar provider, covering multiple therapeutic areas [13][16]. 2. Heparin API Market Improvement - The heparin raw material market is showing signs of recovery, with expectations for price stabilization and potential revenue growth for the company [3][31]. - The company has a strong production and sales level in its heparin API business, which is crucial for funding its injection formulation expansion [36][37]. 3. Focus on Sterile Injection Formulations - The company's injection business has seen significant revenue growth, with a 12.8% increase in 2023 and a compound annual growth rate (CAGR) of 47.4% from 2018 to 2023 [41][46]. - The company has a diverse product line in the injection segment, including low molecular weight heparin and anti-tumor agents, with a strong competitive position in the domestic market [47][55]. 4. Biosimilar Drug Development - The global biosimilar market is projected to grow rapidly, with the company actively developing multiple biosimilar products and securing market entry through strategic acquisitions [67][72]. - The company has made significant progress in obtaining FDA approvals for its biosimilar products, positioning itself as a key player in the U.S. market [72][73]. 5. Financial Projections - The company is expected to achieve substantial profit growth, with projected net profits of 9.0 billion, 11.9 billion, and 15.4 billion yuan for 2024, 2025, and 2026, respectively [5][6].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [5][7]. Core Views - The heparin raw material market is showing marginal improvement, and the company's API business is expected to grow steadily [3][29]. - The company is focusing on sterile injection formulations, with rapid growth in overseas formulation business [4][41]. - The global biosimilar drug market is anticipated to grow significantly, with the company leveraging both self-research and business development (BD) models to expand its growth potential [5][67]. Summary by Sections 1. Company Overview - The company is a leading supplier of heparin raw materials and has been transitioning towards high-end injection formulations and biosimilars, aiming to reduce its reliance on traditional raw material labels [13][16]. 2. Heparin Raw Material Market - The heparin raw material market is expected to recover as supply-side stability and the end of inventory destocking on the demand side are anticipated [3][31]. - The company has established stable supply relationships with major global heparin formulation manufacturers, providing a solid cash flow for its injection business [36][37]. 3. Focus on Sterile Injection Formulations - The company's injection business has shown robust growth, with a revenue increase of 12.8% in 2023 and a compound annual growth rate (CAGR) of 47.4% from 2018 to 2023 [41][46]. - The company has a diverse product matrix in sterile injections, including low molecular weight heparin and anti-tumor agents, with a significant portion of revenue coming from overseas markets [47][55]. 4. Biosimilar Drug Development - The global biosimilar market is projected to grow rapidly, with the company actively pursuing opportunities in this space, including acquiring rights to a biosimilar of adalimumab [5][72]. - The company has multiple biosimilar products in various stages of development, enhancing its growth prospects in international markets [67][72]. 5. Financial Projections - The company is expected to achieve net profits of 0.9 billion, 1.2 billion, and 1.5 billion yuan for the years 2024, 2025, and 2026, respectively, with significant growth rates projected [5][6].

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-008 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于子公司与 Xentria 签署 许可协议暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、本次交易概述 根据协议的约定，在完成 XTMAB 多剂量爬坡试验（MAD）或临床 2 期研究入 组时，支付 2,000 万美元。目前 XTMAB 项目临床 2 期受试者已经筛选完毕，经过 联合指导委员会批准，公司子公司于 2025 年 3 月 5 日向 Xentria 支付 500 万美 元进度款。截至本公告披露日，就 XTMAB 项目公司子公司已累计支付 1,000 万美 元。 三、XTMAB 项目进展情况 XTMAB 是一种肿瘤坏死因子 α（TNFα）抑制剂，旨在稳定免疫失调。TNFα 是炎症的关键调节因子，对肉芽肿的形成至关重要，通常导致疾病进展。目前已 经证明 XTMAB-16 对肺 ...

南京健友生化制药股份有限公司 关于获得国家药品监督管理局 罗库溴铵注射液药品注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）于近 日收到国家药品监督管理局（以下简称"NMPA"）签发的罗库溴铵注射液 5ml： 50mg 及 10ml：100mg 的药品注册证书（药品批准文号分别为：国药准字 H20253446、国药准字 H20253447），现将相关情况公告如下： 一、药品的基本情况 （一）药品名称：罗库溴铵注射液 （二）适 应 症： | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-007 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 公司于 2025 年 02 月 28 日获得 NMPA 通知，公司注册申报的罗库溴铵注射 液（5ml：50mg、10ml：100mg）的化学药品 4 类上市许可申请获得批准。 国内上市原研药参比制剂罗库溴铵注射液（中文商品名为爱 ...

南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）子公司 Meitheal Pharmaceuticals, Inc.（以下简称"Meitheal"）于近日收到美国食品药品 监督管理局（以下简称"美国 FDA"）签发的重酒石酸去甲肾上腺素注射液， 4mg/4mL（ANDA 号：040455）生产场地转移批准信，批准在公司子公司健进制 药有限公司场地生产。现将相关情况公告如下： 一、药品的基本情况 二、药品其他相关情况 公司于 2025 年 2 月 27 日收到美国 FDA 的通知，公司子公司 Meitheal 向美 国 FDA 申报的重酒石酸去甲肾上腺素注射液，4 mg/4 mL（ANDA 号：040455） 生产场地转移至健进制药的申请已获得批准。 | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-006 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 子公司关于获得美国 FDA 重酒石酸去甲肾 上腺素注射液药品生产场地转移注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何 ...

南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）于近 日收到国家药品监督管理局（以下简称"NMPA"）签发的氟维司群注射液 5ml： 0.25g 的药品注册证书（药品批准文号为国药准字 H20253243），现将相关情况 公告如下： 关于获得国家药品监督管理局 氟维司群注射液药品注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-005 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 一、药品的基本情况 （六）申 请 人：南京健友生化制药股份有限公司 二、药品其他相关情况 （一）药品名称：氟维司群注射液 （二）适 应 症： 本品可用于在抗雌激素辅助治疗后或治疗过程中复发的，或是在抗雌激素治 疗中进展的绝经后(包括自然绝经和人工绝经)雌激素受体阳性的局部晚期或转 移性乳腺癌。 本品与阿贝西利联合治疗适用于激素受体（HR）阳性、人表皮生长因 ...